ClinicalTrials.gg
RecruitingNCT07504965DAREUpdated Apr 1, 2026

Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly

An observational study in Mild Cognitive Impairment and Mild Dementia, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Ludwig-Maximilians - University of Munich · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,020
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Cognitive Dysfunction with a site in Germany — 20 open to participants now, 27 under way, 5 of them phase 3. Cognitive Dysfunction · Germany.

Planned enrollment
3rd of 27
1,020 · median 124
Started
2025
with 10 others
Observational
27 of 102
7 open now
Primary completion
2027-07
later than 13 of 26 live
Registered
86th of 102
by date
Lead sponsor
4 of 102
Ludwig-Maximilians - University of Munich

Among the 102 studies in Cognitive Dysfunction with a site in Germany, this one is the 3rd largest by planned enrollment of the 27 observational ones that give a count, is one of 11 that started in 2025, is one of 27 observational ones, reaches primary completion later than 13 of the 26 other live ones, and was the 86th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

20 of the 102 studies in Cognitive Dysfunction with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Cognitive Dysfunction with a site in Germany, or all of them as a file.
02

Study summary

The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort study aiming to identify individuals with cognitive impairments early in pharmacies and enhance their access to support services. Partner pharmacies are equipped with memory test stations, and pharmaceutical staff are trained to guide participants. The digital memory test evaluates cognitive, psychosocial, and health factors, displaying results in a traffic light graphic. Participants with concerning results are referred to specialists or support services.

The study's primary goals are to establish pharmacies as dementia screening hubs, improve care for affected individuals, promote interdisciplinary collaboration, and lay the groundwork for legal and billing frameworks. An optional subproject validates the screening through neurological evaluations.

Read the detailed description

The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort initiative designed to identify individuals with early cognitive impairments through pharmacies, making healthcare and support more accessible. It targets people with initial cognitive symptoms or mild dementia and aims to promote early intervention and improve quality of life.

Key Features:

  • Screening Process: Partner pharmacies (10 across urban and rural settings) are equipped with memory test stations, including tablets for digital cognitive assessments and structured questionnaires. These cover cognitive decline, cardiovascular risk, and depression.
  • Traffic Light System: Results are displayed via a color-coded system (green, yellow, red), guiding next steps for participants, such as seeking medical consultation or accessing support services.
  • Pharmacy Staff Training: Staff receive training to communicate effectively with cognitively impaired individuals and manage the digital tools.
  • Demographic Data Collection: Information such as age, education, and marital status is gathered to understand participant profiles and tailor interventions.

Objectives:

  1. Establish pharmacies as accessible hubs for dementia screening and support.
  2. Evaluate the effectiveness of the screening process and its impact on participants' healthcare behavior.
  3. Validate digital screening tools in non-clinical environments and explore their sensitivity and specificity.

Optional Subproject: A subset of participants undergoes additional clinical validation at the Alzheimer Therapy and Research Center, including neurological exams, imaging, and biomarker analysis.

The study emphasizes privacy through double pseudonymization, secure data handling, and adherence to ethical standards. It seeks to demonstrate the socioeconomic value of pharmacy-based dementia screening and create a framework for broader implementation.

03

Conditions studied

  • Mild Cognitive Impairment
  • Mild Dementia

Keywords

  • Dementia-friendly pharmacies
  • Cognitive impairment
  • Early detection
  • Accessible healthcare
  • Digital cognitive assessments
  • Prevention of dementia
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Study Population:

The study population consists of individuals aged 60 and older, recruited from urban and rural pharmacies. Participants include those with self-reported, relative-reported, or pharmacist-identified cognitive impairments ranging from initial symptoms to mild dementia. The cohort emphasizes diversity, capturing various demographic factors such as migration background, education level, marital status, and living situations, with a focus on underrepresented and underserved groups, including isolated individuals and those in rural areas.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: Participants must be 60 years or older at the time of consent.
  2. Language Proficiency: Sufficient knowledge of the German language to understand instructions and participate in the study.
  3. Cognitive Status: Presence of self-reported, relative-reported, or pharmacist-identified cognitive impairments (e.g., memory problems or mild cognitive changes).
  4. Consent: Ability to provide voluntarily.

Exclusion criteria

Exclusion Criteria

  1. Severe Sensory Impairments: Participants unable to see or hear well enough to complete the digital assessments or questionnaires.
  2. Previous Dementia Diagnosis: Individuals with a prior formal diagnosis of dementia, whether with or without underlying pathology.
  3. Severe Cognitive or Physical Impairments: Any condition that would prevent meaningful participation in the digital tests or structured screening process.

These criteria aim to ensure that the study includes participants at risk of early cognitive decline while excluding those for whom the interventions or assessments would not be feasible or relevant.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,020 participants (estimated)
Patient registry
No

Groups and cohorts

  • prospective cohort study

    The study cohort for the DARE project includes customers and patients from pharmacies located in both urban and rural areas. These participants represent a diverse population segment, including individuals who might not regularly access traditional healthcare services, particularly in rural regions where medical facilities are less accessible. Cohort Details: 1. Eligibility Criteria: * Age: 60 years and older. * Cognitive impairments noted by participants themselves, relatives, or pharmacy staff. * Sufficient understanding of the German language. 2. Inclusion Focus: * Individuals with early cognitive symptoms or mild dementia. * Those potentially underserved by conventional healthcare systems, such as isolated or single individuals.

06

What researchers measure

Primary outcomes

  1. Change in WHOQOL-BREF psychological domain score

    Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire, Brief Version (WHOQOL-BREF). The primary outcome is the change in the psychological domain score from baseline to 24-month follow-up. The psychological domain score will be calculated according to the WHOQOL-BREF scoring manual and transformed to a 0-100 scale, with higher scores indicating better quality of life. Unit of Measure points (0-100 scale) Time Frame Baseline and 24 months

    Time frame: 2025 - 2027

Secondary outcomes

  1. Healthcare utilization: number of healthcare contacts

    Outcome Measure Title: Number of healthcare contacts Description: Healthcare utilization will be assessed using a structured study-specific questionnaire administered via telephone at 12- and 24-month follow-up. The outcome will be the number of healthcare contacts within the preceding 12 months, including visits to general practitioners, medical specialists, hospital admissions, and use of support services (e.g., counseling services, memory clinics, or social support programs). Unit of Measure: Number of contacts (count) Time Frame: 12 months and 24 months

    Time frame: 2025 - 2027

  2. Proportion of participants with new diagnosis of cognitive or neurological disorder

    Description: New diagnoses will be assessed via participant self-report during structured telephone interviews at follow-up. The outcome is defined as the proportion of participants reporting a newly established diagnosis of a cognitive or neurological disorder (e.g., mild cognitive impairment or dementia) since baseline. Where feasible, diagnoses will be verified through available clinical documentation. Unit of Measure: Percentage of participants (%) Time Frame: 12 months and 24 months

    Time frame: 2025 - 2027

07

Study locations

1 of 1 sites recruiting
  • Department of Psychiatry and Psychotherapy, LMU Hospital
    Munich, Bavaria 80336, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 24 months is below that.

Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Apr 1, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07504965
Collaborators
Bayerisches Staatsministerium für Gesundheit, Pflege und Prävention
Responsible party
Carolin Kurz (Dr. med. Carolin Kurz, Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
Apr 1, 2026
Start date
Jul 1, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Carolin I Kurz, M.D.
Contact
psy.alzheimerzentrum@med.uni-muenchen.de
+498944005863

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion